Skip to main content
OpenTrials
Completed

NCT Number: NCT03609528

CamPROBE: Developing a Safer and Simple Device for Local Anaesthetic Transperineal Prostate Biopsies

The CamPROBE study investigates the rate of infective complications using the Cambridge Prostate Biopsy Device method of local anaesthetic transperineal prostate biopsies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital

Cambridge, CB2 0QQ, United Kingdom

About this study

The current method for diagnosing prostate cancer requires a biopsy needle to pass through the bowel wall to reach the prostate. Bacteria in the bowel inevitably enter the urinary system and blood stream. A significant number of men develop infections despite preventative antibiotics (1 in 10 develop fevers/shivers and 1-2 in 100 get a life-threatening infection). It is crucial we find a safer biopsy method for suspected prostate cancer as over 1 million rectal biopsies occur each year.

A safer alternative device was developed, performed under local anaesthetic using the transperineal route: CamPROBE (Cambridge Prostate Biopsy Device). CamPROBE biopsies are taken through the perineum (the area under the testicles), so there is no infection risk, and it's just as good at diagnosing prostate cancer. This investigation progresses from a prototype to a disposable, single use device that any UK hospital can use. The study will assess CamPROBE's ability to reduce infections from prostate biopsies and its usability as an alternative to the current standard biopsies.

Men recommended to undergo a prostate biopsy will be eligible for this multi-centre study. For each patient, the study will take approximately 30 days, consisting of: recruitment, 1 day for the procedure (replaces the standard biopsy pathway) and questionnaires on day 1, 7 and 30. This timeframe will not introduce delays in the patients' normal standard care pathway. Patients will have a transperineal biopsy with CamPROBE instead of the current transrectal method. Biopsy samples will be treated the same as standard procedure. Patients' acceptability of the procedure and complications will be measured using patient self-reported questionnaires.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To be included in the clinical investigation the participant must:

  • Have given written informed consent to participate
  • Be aged 18 years and over
  • Be suitable for a prostate biopsy and clinically due to have a biopsy for diagnostic or surveillance purposes
  • Be willing and able to comply with scheduled visits and completion of study questionnaires

Exclusion criteria

The presence of any of the following will preclude participant inclusion:

  • Contraindication to a prostate biopsy
  • Previous perineal or anal surgery
  • Unable to lie down with legs in a stirrup for at least 45 minutes, as assessed by a clinician

Treatment and study plan

CamPROBE

Device

To be completed

Primary outcomes

  1. Incidence of Infection

    Time frame: 30 days post biopsy

    Changes in incidence of infection as measured using patient self-reported Follow-Up Questionnaires and telephone assessments.

Secondary outcomes

  1. Patient reported pain score

    Time frame: 30 days post biopsy

    Patient reported pain scores as measured using patient self-reported questionnaires.

  2. Biological functions post biopsy

    Time frame: 30 days post biopsy

    Patient biological functions as measured using patient self-reported questionnaires

  3. Patient willingness to have a repeat biopsy

    Time frame: 30 days post biopsy

    Patients' willingness to have a repeat biopsy as measured using patient self-reported questionnaires

Other outcomes

  1. Clinician Perception

    Time frame: 1 day

    Clinician perception of the device and the performance of the CamPROBE assessed using Clinical Performance Assessment questionnaire

Sponsors and collaborators

Lead sponsor

Cambridge University Hospitals NHS Foundation Trust

Other

Collaborators

  • University of Cambridge

Registry information

Acronym: CamPROBE

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Aug 1, 2018
Registry last updated
Dec 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.